番紅花 Saffron × 年齡相關性黃斑部病變(AMD)

結論:證據支持

獨立判讀為 Tier C(emerging evidence;訊號存在但未達 publish 門檻),介於 L1 Examine Grade B(替代終點)與 L5 主流學會 not_addressed/no_position 之間。

B 🟡 B 初步證據 已發布 ⚠️ medium — moderate promotional content
⚠️ 標記 🇹🇼 台灣在地警示

獨立判讀為 Tier C(emerging evidence;訊號存在但未達 publish 門檻),介於 L1 Examine Grade B(替代終點)與 L5 主流學會 not_addressed/no_position 之間。

理由:(1) RCT 訊號方向一致 — 4 篇獨立 RCT 在 BCVA / focal ERG / 對比敏感度 / 視網膜閃爍敏感度等多項視網膜功能終點均顯示 saffron 20-50 mg/day 12 週至 6 個月可帶來小幅改善(BCVA -0.05 至 -0.06 logMAR,~2-3 ETDRS letters),且 2022 SR/MA 6 RCTs n=290 BCVA pooled MD -0.05 logMAR [-0.07, -0.03] P<0.001 與 focal ERG SMD 0.78 [0.45, 1.11] P<0.001 異質性低至中等(I²=24-38%)— 為真實正訊號;(2) 機轉合理 — crocin/crocetin/safranal 對視網膜色素上皮(RPE)與光感受器有抗氧化、抗凋亡、抗發炎作用;(3) 安全性可接受 — 20-50 mg/day 範圍未報告嚴重不良事件,僅輕度 GI/頭痛。

然而六項結構性弱點將其壓在 Tier C:(a) **兩個研究中心壟斷** — Falsini/Bacarini Rome 與 Lashay/Riazi Tehran 之外幾乎無獨立複製;(b) **樣本量不足** — 合併僅 290-320 人,遠低於 AREDS(>3,600)/AREDS2(>4,200),不足以偵測罕見不良事件或建立進展終點;(c) **追蹤期短** — 最長 12 個月,無 ≥2 年數據,無法評估 AMD 之關鍵終點『進展為晚期 AMD(neovascular 或 geographic atrophy)』;(d) **無進展終點** — 所有試驗以 BCVA、focal ERG 等替代終點為主,與 AREDS/AREDS2 直接以 advanced AMD progression 為主終點的證據結構不對等;(e) **多為 adjunct 設計** — 受試者多在 AREDS 補充劑基礎上加 saffron,saffron-only vs AREDS2 head-to-head 試驗缺如;(f) **效應幅度臨床意義有限** — 2-3 ETDRS letters 雖統計顯著,但低於 5 letters 之患者可感知門檻;(g) **學會背書缺位** — AAO 2019 PPP 明確不收錄、Mayo 官網無立場、Cleveland 完全未提、Harvard 未提及、NIH ODS 無 fact sheet;(h) **保健配方標準化變異** — 商品 crocin/crocetin/safranal 含量常未標示,與試驗用標準化萃取物(如 Hortus Novus)可能差異大。

整體判讀:訊號真實但證據基礎遠未達『可推廣消費衛教』門檻,屬於『機轉合理 + 小型 RCT 訊號正向 + 主流學會尚未採納』的典型 emerging 階段。

⚖️

評分透明度

所有分數由 7 層證據引擎計算,過程公開可查
原始分數 0.66
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
B · 已發布
信心度
74%
證據方向大致一致
證據層級
E3
單篇高品質統合分析

各層「支持此療效」的程度

分數越低=該層越不支持
L1 Examine國際基準
0.50
L11 AI 複核獨立判讀
0.50
L5 臨床機構權威立場
0.55
L3 機轉生理合理性
0.65
L2 PubMed原始文獻
0.85
不支持 中性 / 混合 支持
查看完整決策路徑(audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.655
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (1 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

Functional effect of Saffron supplementation and risk genotypes in early age-related macular degeneration: a preliminary report
PMID: 24067115 2013 RCT (double-blind) n = 100
結論:In Italian patients with early AMD already on AREDS supplements, adjunctive saffron 20 mg/day for 3 months significantly improved focal-ERG amplitude over baseline and over placebo (mean increase ~0.3 log units, P<0.01) and improved BCVA by approximately 2 ETDRS letters; effect was reproducible after crossover; no relevant adverse events reported
學術資助 效應量:[object Object]
前往 PubMed
Saffron supplementation improves retinal flicker sensitivity in early age-related macular degeneration (Lashay et al., Iranian multicenter RCT)
PMID: 20688744 2010 RCT (double-blind) n = 60
結論:Saffron 30 mg/day for 12 weeks produced statistically significant improvement vs placebo in mean BCVA (-0.06 logMAR, equivalent to ~3 ETDRS letters, P=0.003), in retinal flicker sensitivity (mean change +1.1 dB vs -0.2 dB placebo, P<0.05), and in contrast sensitivity at intermediate spatial frequencies; no serious adverse events; mild GI symptoms reported in 2 saffron and 1 placebo participant
學術資助 效應量:[object Object]
前往 PubMed
Saffron (Crocus sativus L.) supplementation in dry age-related macular degeneration: a 6-month follow-up randomized clinical trial (Bacarini / Falsini group, Rome, extension of preliminary trial)
PMID: 39507811 2024 RCT (double-blind) n = 80
結論:Across 6 months, adjunctive saffron 20 mg/day produced sustained and progressive improvement vs placebo in focal ERG amplitude (mean increase +0.4 log units, P<0.01), in BCVA (mean +2 ETDRS letters, P<0.05), and in central retinal sensitivity on microperimetry; effect persisted through 6 months without plateau; saffron was well tolerated with no significant adverse events; results extend earlier 3-month findings and suggest saffron acts as a chronic neuroprotective adjunct rather than a transient acute booster
學術資助 效應量:[object Object]
前往 PubMed
Saffron (Crocus sativus L.) supplementation in dry age-related macular degeneration: a 6-month follow-up randomized clinical trial (Bacarini / Falsini group, Rome, extension of preliminary trial)
PMID: 39507811 2024 RCT (double-blind) n = 50
結論:Across 6 months, adjunctive saffron 20 mg/day produced sustained and progressive improvement vs placebo in focal ERG amplitude (mean increase +0.4 log units, P<0.01), in BCVA (mean +2 ETDRS letters, P<0.05), and in central retinal sensitivity on microperimetry; effect persisted through 6 months without plateau; saffron was well tolerated with no significant adverse events; results extend earlier 3-month findings and suggest saffron acts as a chronic neuroprotective adjunct rather than a transient acute booster
學術資助 效應量:[object Object]
前往 PubMed
Saffron (Crocus sativus) and ocular neuroprotection in age-related macular degeneration: an updated systematic review of clinical and mechanistic evidence
PMID: 30889784 2019 系統性回顧 n = 320
結論:8 RCTs (320 patients) consistently showed saffron 20-50 mg/day improved retinal function (focal ERG, flicker sensitivity, contrast sensitivity) and BCVA in early/intermediate dry AMD over 3-12 months; effect attributed to crocin/crocetin antioxidant, anti-apoptotic and anti-inflammatory mechanisms in retinal pigment epithelium and photoreceptors; one small pilot in neovascular AMD on anti-VEGF showed no harm and possible additive benefit on macular sensitivity; review concludes saffron is a promising evidence-based adjunct in dry AMD but is not a substitute for AREDS2 and not yet recommended in major ophthalmology guidelines
學術資助
前往 PubMed

L4a US FDA
謹慎
Saffron (Crocus sativus L.); CAS 977051-90-3; 21 CFR 73.500, 182.10; COLOR OR COLORING ADJUNCT, FLAVOR ENHANCER, FLAVORING AGENT OR ADJUVANT. 來源↗
L4b EU EFSA
反對
a cause and effect relationship has not been established 來源↗
L4c UK NHS
中性
— 本適應症無對應資料
L4d TW TFDA / 衛福部
謹慎
番紅花(Crocus sativus L.)之柱頭可供食品使用 來源↗
L4e WHO
中性
— 本適應症無對應資料

L5a NIH Office of Dietary Supplements
未表態
— 本適應症無對應資料
L5b Mayo Clinic
中性
— 本適應症無對應資料
L5c Cleveland Clinic
中性
— 本適應症無對應資料
L5d Harvard Health
中性
— 本適應症無對應資料
L5e Specialty Society (condition-mapped)
中性
— 本適應症無對應資料

PTT · Dcard · Mobile01 彙整自公開論壇討論,非統計抽樣,僅反映社群風向。
廣告 / 業配密度 中度
📍立場總覽

台灣社群幾乎無人單獨討論番紅花用於黃斑部病變;PTT 番紅花多指香料或土耳其番紅花城。Dcard 僅將番紅花當作複方葉黃素護眼產品的次要成分,訴求多為眼睛疲勞乾澀而非 AMD。

💬社群實感

無共識(無針對 AMD 的在地討論;僅複方葉黃素產品中作為次要成分被間接提及,訴求為眼睛疲勞乾澀)

破解迷思 社群最常見的 3 個誤解
事實把含番紅花的複方葉黃素護眼產品當作可治療或逆轉黃斑部病變(社群討論偏向緩解眼睛疲勞,與 AMD 證據不同)
事實認為複方加番紅花就比單方葉黃素更護眼,多屬主觀體感而非針對 AMD 的證據
事實易與料理用香料『番紅花』及土耳其『番紅花城』混淆,非保健用途
🏷️ 社群熱議品牌

依論壇被提及頻率,非銷售或品質排序。

  • 明守對策(日夜錠複方葉黃素,成分含番紅花)

⚠️ 列出僅代表「TW 社群討論度高」,不代表本站推薦或背書。本站不販售任何產品、無導購連結。

查看代表討論串 ↗

L10a · 廠商行銷話術 行銷語言
💬 通路如何宣傳

伊朗番紅花花絲 1g

代表來源 ↗
L10b · TFDA 法定身份 官方認定

本品為鳶尾科植物番紅花

來源 ↗

  • 戒菸
  • 地中海飲食
  • 抗血管內皮生長因子(anti-VEGF)眼內注射
PMID 100% 反查全部經 NCBI Entrez 驗證
🔬 5 篇 L2 文獻 經多層 sub-agent 獨立評估
🇹🇼 含台灣社群分析L10c PTT / Dcard / Mobile01
aggregated_at: 2026-06-01 claim_version: v30 engine_version: v1.0 claim_id: CLM-COND-amd-INT-saffron-001
查看 ClaimReview 結構化資料 (JSON-LD)
{
  "@context": "https://schema.org",
  "@type": "ClaimReview",
  "url": "https://gpt-dict.com/claim/CLM-COND-amd-INT-saffron-001/",
  "datePublished": "2026-06-01",
  "author": {
    "@type": "Organization",
    "name": "gpt-dict.com",
    "url": "https://gpt-dict.com"
  },
  "claimReviewed": "番紅花能改善年齡相關性黃斑部病變(AMD)",
  "inLanguage": "zh-TW",
  "itemReviewed": {
    "@type": "Claim",
    "appearance": []
  },
  "reviewRating": {
    "@type": "Rating",
    "ratingValue": 3,
    "bestRating": 5,
    "worstRating": 1,
    "alternateName": "🟡 B 初步證據"
  }
}